Cargando…
Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis
We aimed to retrospectively analyze the risk factors of a continuous dienogest (DNG) therapy for serious unpredictable bleeding in patients with symptomatic adenomyosis. This is a retrospective study based on data extracted from medical records of 84 women treated with 2 mg of DNG orally each day be...
Autores principales: | Matsubara, Sho, Kawaguchi, Ryuji, Akinishi, Mika, Nagayasu, Mika, Iwai, Kana, Niiro, Emiko, Yamada, Yuki, Tanase, Yasuhito, Kobayashi, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881344/ https://www.ncbi.nlm.nih.gov/pubmed/31776404 http://dx.doi.org/10.1038/s41598-019-54096-z |
Ejemplares similares
-
Clinical Efficacy of Dienogest versus Levonorgestrel-Releasing Intrauterine System for Adenomyosis
por: Yang, Siyuan, et al.
Publicado: (2022) -
Retracted: Clinical Efficacy of Dienogest versus Levonorgestrel-Releasing Intrauterine System for Adenomyosis
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
The Effects of Dienogest on Macrophage and Natural Killer
Cells in Adenomyosis: A Randomized Controlled Study
por: Prathoomthong, Saowapak, et al.
Publicado: (2018) -
A controlled clinical trial comparing potent progestins, LNG‐IUS and dienogest, for the treatment of women with adenomyosis
por: Ota, Ikuko, et al.
Publicado: (2021) -
The Asian Society of Endometriosis and Adenomyosis guidelines for managing adenomyosis
por: Harada, Tasuku, et al.
Publicado: (2023)